Table: Nxera Pharma -2025 group results (IFRS)

Nxera Pharma

13/02/2026 06:42

Feb 13 (Reuters)- 
              Nxera Pharma Co., Ltd. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                    Year ended      Year ended       Year to        NEXT  
                 Dec 31, 2025    Dec 31, 2024   Dec 31, 2026      YEAR    
                    LATEST         YEAR-AGO        COMPANY      COMPANY   
                   RESULTS          RESULT        FORECAST    H1 FORECAST 
  Sales             29.62            28.84                                
                  (+2.7 pct)     (+125.9 pct)                             
  Operating       loss 8.46        loss 5.42                              
  Pretax          loss 14.95       loss 4.66                              
  Net             loss 12.53       loss 4.84                              
  EPS Basic    loss 138.80 yen  loss 53.92 yen                            
  EPS Diluted  loss 138.80 yen  loss 53.92 yen                            
  Ann Div            NIL              NIL            NIL                  
  -Q2 Div            NIL              NIL            NIL                  
  -Q4 Div            NIL              NIL            NIL                  
 
  NOTE - Nxera Pharma Co., Ltd.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company.
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4565.T